The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.
本公开提供了降低个体神经元或神经胶质细胞中乙酰化Tau
水平的方法,这些方法涉及向个体施用在个体体内转化为
水杨酸盐的原药。本公开提供了治疗个体Tau病的方法,这些方法涉及对个体施用在个体体内转化为
水杨酸盐的原药。